Emcure Pharmaceuticals Limited IPO
Incorporated in 1981, Emcure Pharmaceuticals Limited, an Indian pharmaceutical company, develops, manufactures, and globally markets a wide range of pharmaceutical products across several major therapeutic areas. The company has been ranked 13th in domestic sales among pharmaceutical companies in India for MAT September 2023 and 4th in market share in its covered markets for the same period. Additionally, it is the leading pharmaceutical company in gynaecology and HIV antiviral therapeutic areas for the MAT September 2023. In the six months ended September 30, 2023, and the Financial Year 2023, sales in India contributed 50.84% and 53.16% of the company's total revenue, respectively. The company's Domestic sales grew at a CAGR of 10.80% between September 2019 and September 2023, outperforming the Indian pharmaceutical market.
| Issue Open | 03-07-2024 |
| Issue Close | 05-07-2024 |
| Allotment Date | 08-07-2024 |
| Listing Date | 10-07-2024 |
| IPO Price Band | ₹960 to ₹1008 |
| Minimum Share Bid | 14 |
| Minimum Investment Amount | ₹14112 |
| Total Issue Size | 1,93,65,346 shares (up to ₹1,952.027 Cr) |
| Fresh Issue | 79,36,507 shares (up to ₹800 Cr) |
| Offer For Sale | 1,14,28,839 shares (up to ₹1,152.027 Cr) |
| Face Value | ₹10 Per Share |
| Employee Discount | ₹90 per share |
| Qualified Institutional Buyer [QIB] | 50% |
| High Networth Individual [HNI] | 15% |
| Retail Individual Investor [RII] | 35% |
| Listed on | NSE BSE |
| Listing Date | 10-07-2024 |
| BSE Code | 544210 |
| NSE Code | EMCURE |
| ISIN Code | INE168P01015 |
| IPO Price | ₹ 1008 |
| Lot Size | 14 |
| Expected Listing Price | ₹ 1270 to ₹ 1310 |
| Book Profit | ₹ 1355 |
| Stop Loss | ₹ 1245 |
Can't fetch the data
| Financial Year | Total Asset | Total Revenue | Total Expenses | Profit |
|---|---|---|---|---|
| FY-2021 | - | - | - | - |
| FY-2022 | 6,063.47 | 5,918.86 | - | 702.56 |
| FY-2023 | 6,672.53 | 6,031.72 | - | 561.85 |
| FY-2024 | 7,806.16 | 6,715.24 | - | 527.58 |
| Earnings Per Share [EPS] | ₹ 29.17 |
| Price/Earnings [P/E] Ratio | 34.55 |
| Return on Net Worth [RoNW] | 16.87 % |
| Net Asset Value [NAV] | - |
| Application | Lot Size | Shares | Total Amount |
|---|---|---|---|
| Retail Min | 1 | 14 | ₹ 14,112 |
| Small HNI | 15 | 210 | ₹ 2,11,680 |
| Big HNI | 71 | 994 | ₹ 10,01,952 |
Before applying to any IPO, please thoroughly check the company's fundamentals and financial condition.
www.liveipo.in or its producers are not responsible for any profits or losses. IPO applications are made at your own risk.
We do not buy or sell any IPO applications related to IPO Gray Market Premium. We only provide information.
Do not subscribe to any IPO solely based on Gray Market Premium prices, as they can fluctuate at any time.
We are not Financial Advisors. Please consult your financial advisor before investing or trading.
All updates, posts, and discussions are for educational and learning purposes only.
Our disclaimers and terms & conditions apply to all viewers and members of LiveIPO Groups or Channels.
All content is based on research and case studies from various sources including books, media, and internet.
LiveIPO Group, Channel, Website or App does not provide tips, recommendations, or investment advice.
Group Admins or Owners are not responsible for any financial losses.
We do not publish any stock market magazines.
We are not SEBI registered analysts.
Stock Market investments are subject to market risk.
The content provided in this application is for educational and informational purposes only. It does not constitute financial advice to buy or sell securities, invest in IPOs, or make any other financial decisions. All information reflects data and market perceptions as of the publication date. We are not SEBI-registered analysts. Please consult a qualified financial advisor before making investment decisions. By using this app, you agree to our terms and conditions.
© 2024 LiveIPO. All rights reserved.